
    
      COGNATE is an acute, confirmatory prospective, multi-center study designed to gather data on
      Brady and CRT-P indicated patients, with no restrictions on the type/brand of leads. This
      study will enroll up to 80 patients in up to 12 centers. Total duration of the study is
      expected to be 9 months.
    
  